Maya Ridinger

9PUBLICATIONS
66CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 18, 2025
Targeting PLK1 Reduces MMP10 to Enhance Radiosensitivity in HPV- Head and Neck Cancer.

Julianna Korns, Maria A Lehn, Shreya Shyamsunder

|Jun 26, 2025
Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas.

Federica Guffanti, Ilaria Mengoli, Francesca Ricci

|Mar 20, 2025
PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia.

Aditya S Sheth, Ka-Kui Chan, Sheng Liu

|Oct 30, 2024
Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial.

Daniel H Ahn, Maya Ridinger, Timothy L Cannon

|Oct 16, 2024
PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights.

Sreeja Sreekumar, Elodie Montaudon, Davis Klein

|Jul 22, 2024
Onvansertib treatment overcomes olaparib resistance in high-grade ovarian carcinomas.

Michela Chiappa, Alessandra Decio, Luca Guarrera

Pageof 2

Frequent Collaborators

4 joint publications

Peter J P Croucher

3 joint publications

Heinz-Josef Lenz

2 joint publications

Andreas Varkaris

2 joint publications

Susan L Dalrymple